Human medicines European public assessment report (EPAR): Vildagliptin / Metformin hydrochloride Accord, vildagliptin,metformin hydrochloride, Date of authorisation: 24/03/2022, Revision: 4, Status: Authorised

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants

Saxenda

ICH Guideline M13B on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver - Scientific guideline

Overview of comments received on ICH M13B guideline on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver (EMA/CHMP/ICH/85092/2025)

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Date of authorisation: 19/09/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Ifinwil, eflornithine, Status: Application withdrawn

HMPC meeting report on European Union herbal monographs, guidelines and other activities - 07-09 July 2025